ABSTRACT
AIMS: We aimed to confirm the hypothesis that dysglycaemia including in the pre-diabetes range affects a majority of patients admitted with acute coronary syndrome (ACS) and is associated with worse outcomes. METHODS: In this prospective observational cohort study, consecutive inpatients agedâ¯≥â¯54â¯years with ACS were uniformly tested and categorised into diabetes (prior diagnosis/ HbA1câ¯≥â¯6.5%, ≥48â¯mmol/mol), pre-diabetes (HbA1c 5.7-6.4%, 39-47â¯mmol/mol) and no diabetes (HbA1câ¯≤â¯5.6%, ≤38â¯mmol/mol) groups. RESULTS: Over two years, 847 consecutive inpatients presented with ACS. 313 (37%) inpatients had diabetes, 312 (37%) had pre-diabetes and 222 (25%) had no diabetes. Diabetes, compared with no diabetes, was associated with higher odds of acute pulmonary oedema (APO, odds ratio, OR 2.60, pâ¯<â¯0.01), longer length of stay (LOS, incidence rate ratio, IRR 1.18, pâ¯=â¯0.02) and, 12-month ACS recurrence (OR 1.86, pâ¯=â¯0.046) after adjustment, while no significant associations were identified for pre-diabetes. Analysed as a continuous variable, every 1% (11â¯mmol/mol) increase in HbA1c was associated with increased odds of APO (OR 1.28, Pâ¯=â¯0.002) and a longer LOS (IRR 1.05, Pâ¯=â¯0.03). CONCLUSIONS: The high prevalence of dysglycaemia and association with poorer clinical outcomes justifies routine HbA1c testing to identify individuals who may benefit from cardioprotective anti-hyperglycaemic agents and, lifestyle modification to prevent progression of pre-diabetes.
